Move over oncology — I&I will write the next big stories in innovation

As the shine on oncology dims for investors and drug developers, the new darlings are immunity and inflammation, as well as neurology, another sign that biotech is entering an era of the large population diseases that fell by the wayside for so long. This sits alongside patchwork enthusiasm for precision medicine and its potential to deliver meaningful gains in innovation in the next three years. 

Those are the top messages from a survey of 45 biotech executives and investors conducted by BioCentury between Oct. 23 and Nov. 27. Respondents were evenly split between corporate executives (23), mostly in biopharmas, and finance executives (22), including 20 VCs and two bankers. ...